Addition Therapeutics vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Emerged from stealth with $100M (Dec 2025) backed by Gates Foundation, SR One, Abingworth. PRINT LNP platform integrates RNA at specific genomic loci — potentially re-dosable gene therapy for rare and chronic diseases.
About
Addition Therapeutics emerged from stealth in December 2025 with $100 million in financing backed by the Gates Foundation, SR One, and Abingworth, developing PRINT — a platform using lipid nanoparticles (LNPs) to deliver RNA and enzyme payloads that integrate therapeutic sequences at specific genomic loci. Unlike traditional AAV gene therapy (which requires viral vectors and can only be dosed once due to immune response), PRINT's non-viral approach is potentially re-dosable, opening gene therapy to chronic diseases beyond rare genetic disorders.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease; pivoting to mRNA cancer immunotherapies with BNT111 melanoma vaccine evaluated in combination with Regeneron's cemiplimab as key pipeline asset.
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Addition Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.